Summarized by Masters of Longevity from Longevity Technology.
Enveda closed a $311 million financing to advance AI-guided natural product drug candidates, with several molecules moving toward later clinical testing.
Key Takeaways
- Enveda raised $311 million in a financing round led by Catalio Capital Management.
- The company has produced 17 development candidates and has three programs currently in human trials.
- ENV-308 reduced circulating leptin and was well tolerated in an 88-person healthy volunteer study.
